Funder: National Institutes of Health
Due Dates: May 7, 2025 | September 7, 2025 | January 7, 2026 | February 19, 2026 (NOFO expiration)
Funding Amounts: Up to $500,000 direct costs per year, maximum project period 5 years; total estimated program funding $500,000.
Summary: Supports research on the impact of defective HIV proviruses on HIV persistence, pathogenesis, and implications for cure strategies during antiretroviral treatment.
Key Information: Clinical trials are not allowed; human samples are required for all projects.